IP Library Granted Patent US 11,912,702
Granted Patent B2
US 11,912,702 · App. 17/558,840 · Granted Feb 27, 2024

Substituted pyridines as inhibitors of histone deacetylase

Inventors: Nathan Oliver Fuller (Arlington, MA); John A. Lowe, III (Stonington, CT)
Assignee: Alkermes, Inc.
C07D471/04C07D487/04C07D513/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,912,702
App. No.
17/558,840
Granted
Feb 27, 2024
Kind
B2
Abstract

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).

Claims (20)

1. A method for treating a cognitive function disorder, a cognitive function impairment, or a psychiatric disorder in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt of any of the foregoing.

2. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

9. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

Assignments (5)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073790/0950 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (072656/0509) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES, INC.
Reel/Frame 074858/0481 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES, INC.
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 072656/0509 →
CHANGE OF NAME Recorded Jan 17, 2024
From: RODIN THERAPEUTICS, INC.
To: ALKERMES, INC.
Reel/Frame 066148/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2023
From: FULLER, NATHAN OLIVER; LOWE, III, JOHN A.
To: RODIN THERAPEUTICS, INC.
Reel/Frame 065271/0666 →
Continuity (3)
Continuation 16636969
Provisional Application 62541807 · Aug 7, 2017
Related Publication 20220340558A1 · Oct 27, 2022